key: cord-0941551-umpbgyji
authors: van Blydenstein, Sarah Alexandra; Menezes, Colin Nigel; Miller, Nicole; Johnson, Naomi; Pillay, Bavinash; Jacobson, Barry F.; Omar, Shahed
title: Prevalence and Trajectory of COVID-19-Associated Hypercoagulability Using Serial Thromboelastography in a South African Population
date: 2021-12-22
journal: Crit Care Res Pract
DOI: 10.1155/2021/3935098
sha: ecc5fac4624008d7561f08823322cda5a95ba221
doc_id: 941551
cord_uid: umpbgyji

INTRODUCTION: The coagulation abnormalities resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been attributed to inflammation and subsequent cytokine storm. Thromboelastography (TEG) is a point-of-care test used to assess clot formation and degradation in whole blood and is an indicator of the overall real-time coagulopathic state of the patient. METHODS: A single-centre, prospective, observational cohort study was conducted in South Africa, analysing the coagulation patterns of 41 patients with hypoxia related to SARS-CoV-2 using serial thromboelastography (TEG) on admission, after 48 hours, and at resolution of hypoxia/day 10. Results: Two-thirds (n = 26) were women. The median age was 61 (IQR 50–67), and the majority (88%) were Black patients. Almost half (22) of the patients were critically ill and ventilated, with median SOFA and SAPS2 scores of 3 and 22 (IQR2-4 and 18–30), respectively. The prevalence of hypercoagulability was 0.54 (95% CI 0.46–0.62), whilst 29/41 (0.71, CI 0.64–0.78)) met the definition of hypofibrinolysis. Differences between the hypercoagulable (HC) and non-hypercoagulable groups remained apparent at 48 hours after anticoagulation. At this time point, the K time was significantly lower (p ˂ 0,01), and the α-angle (p ˂ 0,01) and maximum amplitude (MA) (p ˂ 0,01) were significantly higher in the HC cohort. At resolution of hypoxia, or day 10, only MA was significantly higher in the hypercoagulable group compared to the non-hypercoagulable group (p = 0.01). The initial impairment in fibrinolysis (Ly30), α angle, and MA were significantly associated with mortality, with p values of 0.006, 0.031, and 0.04, respectively. CONCLUSIONS: In this South African population, hypercoagulability was a highly prevalent phenomenon in COVID-19 disease. It was typified by hypofibrinolysis and a persistently elevated MA, despite anticoagulation therapy.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), a multisystem disease, which is typified by hypoxia, inflammation, increased microthrombosis and macrothrombosis [1] [2] [3] [4] , and fibrinolysis shutdown [5, 6] . HC has been characterised using various viscoelastic tests (VETs), specifically thromboelastography (TEG).

Severe COVID-19 is associated with coagulation abnormalities, specifically a raised D-dimer and an increased fibrinogen, which correlates with a worse prognosis [7] and an increased risk of thrombotic events [7] [8] [9] , and is not consistent with a disseminated intravascular coagulopathy (DIC) [9] [10] [11] or a consumptive process. [7] e aetiology of hypercoagulability may be linked to endothelial inflammation, neutrophil extracellular traps, and increased platelet activity with increased microvesicles. [11, 12] .

Currently, there is no gold standard definition of hypercoagulability as defined by TEG parameters, but HC is typified by a low Ly30 < 1%, a MA > 69 mm, an α-angle of >77°, R-time of < 4.3 minutes, and a K-time of < 0.8 minutes [9, 11, [13] [14] [15] . ese findings demonstrate a decreased clot formation time, an increased clot strength, and impairment of the fibrinolytic system. Variations in the definition of HC include combinations of abnormalities in MA, clot formation time, and α-angle. [5, 7, 10, 15, 16] is COVID-19associated state of hypercoagulability and impaired fibrinolysis has been associated with an increased risk of thromboembolism [5, 7, 11] and thrombotic events, respectively. [6] .

ere have been several studies [6, 7, 10, [15] [16] [17] assessing TEG abnormalities at a single time point and even fewer at another point during COVID-19 infection. [8, 9, 11] .

Using a robust definition that included one hypercoagulant/procoagulant parameter in addition to impaired lysis, we sought to determine an accurate estimate of the prevalence of COVID-19-associated hypercoagulability. In addition, we performed two further TEG assessments to describe the dynamic changes after 48 hours of anticoagulation and at resolution/day 10 of hypoxemia. To our knowledge, this is the first study in the South African population.

is was a prospective, observational, cohort study of COVID-19 adult patients in a South African hospital.

All patients aged 18 years and older who tested positive for the SARS-CoV-2 using polymerase chain reaction (PCR) assay and were admitted between November 2021 and March 2021 were considered for enrolment and were sequentially approached during weekday office hours. Patients were included if they were expected to survive for longer than 48 hours and met the criteria for severe disease or critical illness. Severe disease was defined as oxygen saturation ≤ 92% with a respiratory rate ≥ 25 and, therefore, requiring supplemental oxygen support without the need for invasive or noninvasive ventilation. Critical illness was defined as hypoxemia and the need for additional ventilatory support, in the form of noninvasive or invasive ventilation. We excluded patients if they were pregnant, on oestrogen replacement therapy, and chronic anticoagulation therapy, including, but not limited to, aspirin, warfarin, clopidogrel, heparin, enoxaparin, and direct-acting oral anticoagulants. [18] , sepsis-induced coagulopathy (SIC) score [19] , simplified acute physiology score 2 (SAPS2) [20] , and sequential organ failure assessment (SOFA) scores [21] , at the above three time points unless the enrolled subject was discharged or demised before the defined time.

® 6s Methodology and Study Definitions [22] . e TEG is a point-of-care test, is used to assess the formation and degradation of a clot in whole blood, and demonstrates abnormalities in coagulation, which may not be apparent when using standard coagulation tests including prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet number, and antithrombin. TEG ® 6s assays employ various activators, including kaolin, heparinase, and tissue factor. e reaction time (R) describes the time to initial fibrin formation and 2 mm amplitude (initiation phase) and informs about clotting factors. e kinetic (K) time is the time taken to achieve a given clot strength of 20 mm amplitude (amplification phase) and indicates the initial phase of fibrin cross-linking. e α-angle measures the speed of clot formation and assesses the thrombin burst (propagation phase). Both the K-time and α-angle are dependent on fibrinogen. e maximum amplitude (MA) indicates the maximum strength of the clot and depends on platelet function and the contribution of fibrin. e lysis time at 30 minutes (Ly30) indicates the amount of fibrinolysis within 30 minutes of MA. [22] . 2 Critical Care Research and Practice

We used a strict study definition for hypercoagulability (HC) requiring the presence of both an abnormality of lysis (low Ly30) and at least one of the following: a reduced Rtime, reduced K-time, elevated α-angle, or an elevated MA on admission.

Enoxaparin dosing was based on the COVID-19 hospital protocol. erapeutic dosing was used when there was an increased risk of hypercoagulability based on an elevated D-dimer, in the face of critical illness and severe hypoxemia or in the presence of thromboembolic events. Alternatively, prophylactic enoxaparin was administered if patients were hypoxemic, had a normal D-dimer level, and had no contraindication to enoxaparin administration. TEGs were performed at admission before anticoagulation administration and, at time points 2 and 3, were performed 3-4 hours after the anticoagulation dose to standardise the effect of anticoagulation and measure antifactor 10 a. All patients received appropriate anticoagulation as per hospital protocol.

We applied the study definition of HC to the patient data to calculate the prevalence of HC. We described the trajectory of TEG parameters using data from admission, after 48 hours, and at resolution. We used the admission non-TEG characteristics to describe the hypercoagulable and non-hypercoagulable states. Lastly, we described the TEG and non-TEG characteristics and their association with mortality. Continuous variables are expressed as median (interquartile range (IQR)), and proportions/percentages were used for categorical variables. Continuous data were compared using the Mann-Whitney U test, whilst proportions were compared using the chi-square test. A p-value < 0.05 was considered statistically significant. We based our sample size on the minimum number of 12 required per group as a rule of thumb for a pilot study. [23] Assuming a mortality rate of 40%, we required a minimum sample size of 20 per group.

Approval was received from the University Human Research Ethics Committee (Medical), M200728. Written informed consent from the patient or patient surrogate was obtained as per local ethics committee guidelines.

were included from 4 November 2020 and 23 March 2021. All patients (41) had a TEG on admission, 38 had a second (at 48 hours after admission), and 25 had a third (either on day ten if still hypoxemic or at the resolution of hypoxemia, whichever came first). Two-thirds (n � 26, 63%) were women. e median age was 61 years (IQR 50-67). e majority (88%) were Black patients. e median SAPS II score was 22 .

Almost half (22/41, 54%) of the patients were critically ill and ventilated, and 19 were classified as "severe disease" (not ventilated but hypoxic and requiring supplemental oxygen therapy). On the day of admission, the median SOFA score was 3 (IQR 2-4), ISTH DIC score was 2 (IQR 0-2), and median SIC score was 2 (IQR 2-3). Half (54%) of enrolled patients had coexistent hypertension, 41% had diabetes mellitus, 39% had human immunodeficiency virus (HIV), and 15% were obese.

Overall, 20 of 39 (51%) patients were placed on therapeutic anticoagulation, and 19 of 39 (49%) were placed on prophylactic doses of enoxaparin. ere were no differences in the proportion of patients on therapeutic anticoagulation between the HC and non-HC group, X [2] � 0.24, p � 0.62.

Twenty-two of the 41 (54%) patients met the study definition of hypercoagulability (HC) with a prevalence of 0.54 (95% CI 0.46-0.62), whilst 32/41 (prevalence of 0.78, CI 0.72-0.85) met the definition of hypofibrinolysis with Ly30 < 1%. Using a Ly30 threshold of ≤0.1%, the prevalence was 0.71 (CI 0.64-0.78).

Resolution. Hypercoagulability was defined by admission (T1) TEG parameters. Differences between the hypercoagulable and non-hypercoagulable groups become more apparent at 48 hours implying that there is a progression of the HC state, which only starts resolving after at least 48 hours. Although the α-angle and MA trended higher at baseline, these differences did not reach a significant statistical difference until 48 hours later. At 48 hours, the K-time is significantly lower (p˂0.01the α-angle (p˂0.01) and MA (p˂0.01) is significantly higher in the HC cohort. At resolution of hypoxia, or day 10, only MA was significantly and persistently higher in the hypercoagulable group compared to the non-hypercoagulable group (p � 0.01). As shown in Table 1 and Figure 1 , this difference was driven by survivors (80%). At both 48 hours and resolution, median anti-Xa levels were within the range for anticoagulation prophylaxis, 0.42 (0.21-0.52) and 0.4 (0.27-0.84), respectively, within the HC group, and 0.42 (0.21-0.59) and 0.37 (0.26-0.7) in the non-HC group.

As shown in Table 2 , platelet count at admission was significantly higher in the hypercoagulable group. ere was also a trend to a lower haemoglobin level in the HC.

Mortality. Admission SOFA score, SAPS 2 score, and LDH were significantly higher amongst nonsurvivors. e initial impairment in fibrinolysis (Ly30), α-angle, and MA were significantly associated with mortality. As shown in Critical Care Research and Practice Table 3 , there was a trend to a higher D-dimer value amongst nonsurvivors.

Severe COVID-19 is associated with coagulation abnormalities, known as CAC, specifically a raised D-dimer, which correlates with a worse prognosis [7] and an increased risk of thrombotic events. [14] e coagulation abnormalities are considered to be a hypercoagulable state typified by increased fibrinogen and increased D-dimers [7] [8] [9] and are not consistent with a disseminated intravascular coagulopathy (DIC) [9] [10] [11] or a consumptive process. [7] e aetiology of hypercoagulability may be linked to endothelial inflammation, neutrophil extracellular traps, and increased platelet activity with increased microvesicles. [11, 12] .

Whilst traditional coagulation tests have been useful in the measurement of CAC, TEG is a point-of-care test used to assess the clot formation and degradation in whole blood in real time and can identify the individual contributions of the endothelium, the platelets, and the clotting factors. e fibrinolysis shutdown, described by Tsantes et al. [15] as maximum Ly30 < 3.5%, cannot be appreciated using conventional coagulation parameters. ere have been several studies [15] looking at predominantly single-time point TEG assessments in critically ill patients with COVID-19, with some [8] having a repeat TEG, but for the first time, a third TEG assay was performed in this study of serial TEGs in patients with COVID-19, at time of resolution of hypoxia or day ten of illness.

e main finding was that half of the study population (54%) met the study definition of hypercoagulable state on their initial TEG, and 71% had a Ly30 ≤ 0.1%. No patients met the ISTH DIC criteria, with a mean DIC score of 2, and a mean SIC score of 2. e range of HC documented in studies has been variable. Considering clot lysis time alone as a of 0%. is study used a threshold for Ly30 of less than or equal to 0.1%, and our data showed a high prevalence (71%) of hypofibrinolysis [14] . Hypofibrinolysis on its own is an insufficient marker of abnormal coagulation, and at least one other TEG marker indicating increased clot burden may be found in 20% of "healthy" individuals. [24] To ensure robustness, our definition of hypercoagulability required both a lysis abnormality and one other TEG abnormality. e prevalence of COVID-19-associated HC ranges from 30% [16] (considering either an increased MA, K-time, or α-angle) to 74% [25] when only a MA > 69 mm is considered. Our proposed definition yields a prevalence of 54%, which may be less prone to overestimation and underestimation. Aside from the absence of a gold standard definition, the timing of the viscoelastic test (VET) is likely to impact prevalence estimates. is is evident with studies conducting VET up to two weeks from admission. [26, 27] We chose to define HC based on admission TEG parameters to avoid the effects of anticoagulation. ere may be additional heterogeneity based on different commercially available VET manufacturers (ROTEM, TEG, Quantra, and ClotPro) and differences in the patient population. Whilst our study provides the first data from South Africa in a predominantly Black population (88%), the effect of different analysers requires further investigation.

Despite similar anticoagulation strategies with similar proportional utilisation of prophylactic and therapeutic anticoagulation in the two groups, the HC group showed a significantly greater persistence of a functional procoagulant state over time. is is demonstrated with the hypercoagulable group demonstrating a shorter amplification (K-time) and greater propagation (higher α-angle) at 48 hours compared to the non-hypercoagulable group. ere are no other data that we could find in the literature to compare these findings with. Both these processes normalise compared to the non-HC group by day 10/resolution. Two factors can be postulated to contribute to this change. e first is likely the effect of the administered anticoagulant, and the second may be the improvement of the HC state with disease resolution over time. After the administration of heparin in both groups, there was a nonstatistical increase in R-time between admission (preheparin) and 48 hours after admission (3 hours after the fourth dose of heparin). It is difficult to interpret the effect of heparin on the R-time as we used a heparinase-corrected reading, which may attenuate the increase in R-time.

e evolution of the functional coagulation variable relating to maximal clot strength (MA) is of great interest. e MA was significantly elevated and greater in the HC group when compared to the non-HC group. is elevation was present at 48 hours and persisted to resolution and/or day 10.

is was found despite similar anticoagulation strategies and efficacy (anti-Xa levels). is difference was driven by the findings in the survivors (80% of those with TEGs at T3). Bocci et al. [8] described a similar persistence of TEG abnormalities at seven days despite therapeutic-dose anticoagulation.

Notably, 80% of clot strength and integrity are dependent on platelet function. [22] Our intervention included full anticoagulation for roughly half of the hypercoagulable group, whilst Bocci et al. used full anticoagulation for the entire group. e delayed persistence of this elevation may indicate that even therapeutic anticoagulation may not be able to completely reverse this hypercoagulable state.

Consideration should be given to the role of platelet aggregation, platelet hyperactivity, and microthrombus formation as these may be a neglected part of the pathophysiologic process of severe COVID-19. [28, 29] e MA represents the eventual strength of the fibrin clot and is not only predominantly dependent on platelet count in non-COVID-19 patients, interacting via GPIIb/IIIa, but also on fibrin. Fibrin has been thought to be the dominant role player in clot strength in patients with COVID-19. [30] e persistently elevated MA despite the resolution of hypoxia results in the continued stimulation of platelet activity in the damaged endothelium, particularly of the lungs, and the role of antiplatelet therapy may require further investigation within this cohort of patients. e mechanism of platelet abnormality is multifactorial. ere are HC and endothelialitis that occur with SARS-Co-V-2 infection, exacerbated by hypoxia (itself a platelet activator), and the milieu becomes procoagulant and proinflammatory. [2] Neutrophil extracellular traps may also play a role in initiating coagulation [2] , as may an autoimmune component to the thrombocytopenia triggered by SARS-Co-V-2, or direct infection of the haemopoietic cells, as was seen in SARS, a similar coronavirus.

ere have also been studies showing a normal [9] or increased platelet count [11] , and possible causes include hypoxia with stimulation of hypoxia-inducible factor and increased megakaryocyte activity within the lung and bone marrow. [31] Furthermore, the spike protein of SARS-Co-V-2 can directly stimulate platelets. [32] Our own findings suggest an association between a higher platelet count and this state.

Hranjec et al. used platelet mapping and VET to guide the treatment of patients with COVID-19, and they corrected the platelet-induced aspect of the coagulopathy with either aspirin or clopidogrel or both (in addition to heparin), which was associated with improved outcomes. Viecca et al. performed a proof-of-concept case-control study and showed that patients treated with acetylsalicylic acid and clopidogrel had a reduction in alveolar to arterial oxygen gradient, consistent over seven days, with a concomitant increase in PaO2/FiO2 ratio, with no bleeding incidences. [33] . e fibrinolysis shutdown (Ly30) in our study was significantly lower in the nonsurvivors. is has been previously described, with Wright et al. [6] demonstrating a correlation between fibrinolysis shutdown and thrombotic events, and Bocci et al. [8] demonstrated a worse 28-day outcome within the group who had Ly30 < 1% and an elevated D-dimer, and an association between HC and rate of thrombotic events (TEs) and renal failure [6, 11, 34] amongst patients with COVID-19. e median α-angle (clot propagation) was approximately 76°in nonsurvivors and 78°in survivors. Although this was statistically different, it is unlikely that these are clinically different as they both hover around the upper reference limit and the coefficient of variation of the assay is certainly larger than this difference. A similar relationship between MA and mortality is present. Both survivors and nonsurvivors have an elevated MA, but the absolute difference (0.8 mm) is unlikely to be clinically important. It is likely that we should, therefore, consider hypercoagulability as a continuum of effect, and larger studies may be required to establish clinical thresholds. e combination of hypofibrinolysis and persistently increased MA alludes to the as yet not fully understood COVID-19 coagulopathy but suggests that platelets should not be overlooked and speaks to the complex nature of the disease process.

is study was limited by its observational nature. Furthermore, it was a small study, at a single centre, and thromboembolic events were not assessed.

In this South African population, hypercoagulability is a highly prevalent phenomenon in COVID-19 disease. It is typified by hypofibrinolysis and a persistently elevated MA, despite anticoagulation therapy. 

Anonymised supporting data will be made available upon request in an Excel spreadsheet.

Approval was received from the University Human Research Ethics Committee (Medical), M200728.

Written informed consent from the patient or patient surrogate was obtained as per local ethics committee guidelines.

Qiagen had no role in the study design, collection, analysis, and interpretation of data, in writing of the report, or in the decision to submit the article for publication.

No author has any conflict of interest to declare.

SAVB contributed to the conception, design of the work, data and sample collection, and interpretation of data, drafted the work, substantively revised it, approved the submitted version, and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. CNM contributed to the conception and design of the work, substantively revised it, approved the submitted version, and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. NM contributed to data collection and sample collection, substantively revised it, approved the submitted version, and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. NJ contributed to data collection and sample collection, substantively revised it, approved the submitted version, and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. BP contributed to data collection and sample collection, substantively revised it, approved the submitted version, and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not Critical Care Research and Practice personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. BFJ contributed to the conception and design of the work, substantively revised it, approved the submitted version, and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. SO contributed to the conception, design of the work, analysis, and interpretation of data, substantively revised it, approved the submitted version, and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19

Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia

Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection

COVID-19-Related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure

romboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study

Complex and prolonged hypercoagulability in coronavirus disease 2019 intensive care unit patients: a thromboelastographic study

In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation

Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis

COVID-19-associated coagulopathy: an exploration of mechanisms

romboelastography findings in critically ill COVID-19 patients

e role of TEG analysis in patients with COVID-19-associated coagulopathy: a systematic review

COVID-19 infection-related coagulopathy and viscoelastic methods: a paradigm for their clinical utility in critical illness

romboelastography findings in critically ill COVID-19 patients

High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there

Guidelines for the diagnosis and management of disseminated intravascular coagulation

New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey

A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study

Use of the SOFA score to assess the incidence of organ dysfunction/ failure in intensive care units. Working group on "sepsisrelated problems" of the European Society of Intensive Care Medicine

New uses for thromboelastography and other forms of viscoelastic monitoring in the emergency department: a narrative review

Sample size of 12 per group rule of thumb for a pilot study

Establishment of the normal reference range of thrombelastogram among the healthy population and pregnants in China

Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients

Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia

romboembolism, hypercoagulopathy, and antiphospholipid antibodies in critically ill coronavirus disease 2019 patients: a before and after study of enhanced anticoagulation

Platelet gene expression and function in patients with COVID-19

Coronavirus disease 2019-associated coagulopathy

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit

A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study

romboelastographic results and hypercoagulability syndrome in patients with coronavirus disease 2019 who are critically ill

TEG ® 6s cartridges were provided by Qiagen.